Investors weighing large-cap pharmaceutical exposure in 2026 face a genuine dilemma between Amgen (AMGN) and Bristol Myers Squibb (BMY).
Both companies supply essential medicines to millions of patients, but their financial profiles point in markedly different directions for prospective shareholders.
Amgen trades at $438.94 with a market cap of approximately $230 billion, while Bristol Myers Squibb trades at $61.68 with a market cap closer to $120 billion.
The valuation gap between the two is significant, with Amgen carrying a price-to-earnings ratio of 26.40 compared to Bristol Myers Squibb’s considerably cheaper 12.96.
Amgen focuses on biologics and complex medicines for serious illnesses, with a strong presence in oncology and rare disease treatments across global markets.
The company sells its products primarily through three major distributors, McKesson Corp., Cencora, and Cardinal Health, creating notable customer concentration risk for investors to consider.
Amgen posted revenue of close to $36.8 billion for fiscal year 2025, representing growth of roughly 10% compared to the prior year, a meaningful expansion for a company of its size.
Its free cash flow reached nearly $8.1 billion for the year, and the company offers a dividend of $9.94 per share, yielding approximately 2.34% at current prices.
Bristol Myers Squibb reported fiscal year 2025 revenue of roughly $48.2 billion, though that figure was nearly flat compared to the prior year, reflecting a more mature revenue base.
The company generated approximately $12.8 billion in free cash flow, nearly 60% more than Amgen, making it one of the stronger cash generators among large pharmaceutical peers.
Bristol Myers Squibb’s net income for the fiscal period came in at about $7.1 billion, with a net margin of approximately 14.6%, reflecting the substantial costs associated with research and drug development.
The company’s dividend stands at $2.52 per share, delivering a yield of roughly 4.28%, which is notably more attractive than Amgen’s yield for income-focused investors.
Bristol Myers Squibb carries a debt-to-equity ratio of approximately 2.6x, meaningfully lower than Amgen’s ratio of around 6.3x, suggesting a comparatively less leveraged balance sheet structure.
However, Bristol Myers Squibb faces serious headwinds from the Inflation Reduction Act, which targets key products including Eliquis and Pomalyst for government-negotiated drug pricing.
Patent expirations for major drugs and ongoing legal challenges from generic manufacturers add further layers of uncertainty to the company’s future revenue trajectory.
The company is also managing a reinstated $6.7 billion lawsuit related to its Celgene acquisition, alongside the complex integration of several other recent acquisitions.
Amgen’s gross margin of 72.71% edges out Bristol Myers Squibb’s 66.64%, reflecting the pricing power and production efficiencies that biologics can command in the marketplace.
For growth-oriented investors, Amgen’s stronger revenue momentum and expanding pipeline may justify its premium valuation relative to its more value-priced pharmaceutical peer.
For those prioritising income and deep value, Bristol Myers Squibb’s higher free cash flow, lower earnings multiple, and superior dividend yield present a compelling alternative case.
The choice between AMGN and BMY ultimately depends on whether an investor prioritises growth potential or value-driven income within the large-cap healthcare sector in 2026.
